Should you buy DNA (DNA) stock in 2022?

In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021. According to 4 analysts, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $1.88, which is an increase of 16.77% from the latest price.

Is Ginkgo Bioworks (DNA) a good stock to buy?

Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021. According to 4 analysts, the average rating for DNA stock is "Sell."

Is DNA a good buy entry?

$DNA - Update NYSE:DNA is losing steam and appears to be entering a breakdown. Waiting to enter until around $1.60 - $1.70.NYSE:DNA is losing steam and appears to be entering a breakdown. Waiting to enter until around $1.60 - $1.70. DNA- A good buy entry DNA stocks has many good support to buy: -Key level.

Is DNA trading at a 44% discount?

DNA is trading at a 44% discount. Is it the right time to buy, sell, or hold? Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DNA is a good fit for your portfolio.